Molecular Partners Inks License Deal With Novartis For $580M

Molecular Partners AG MOLN entered into a license agreement with Novartis AG NVS to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies (DARPin-RLTs).

  • According to the license agreement, Novartis will pay $20 million upfront to Molecular Partners. The total deal amount also includes milestone payments of up to $560 million and a low double-digit percentage of royalties.
  • Novartis will be responsible for all clinical development and commercialization activities.
  • The collaboration will allow Molecular Partners to team up with Novartis to discover DARPin-RLTs targeting specific tumor-associated antigens.
  • "DARPins have great potential to enable robust, tumor-specific delivery of radioligands owing to their small size, allowing for greater tumor penetration and high specificity and affinity," Molecular Partners said in a statement.
  • Price Action: MOLN shares are up 8.7% at $15.86, NVS stock is down 0.24% at $80.66 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!